Merck KGaA Expand its Collaboration with NKMax to Evaluate the Combination of SNK01 + Erbitux (cetuximab) for Metastatic NSCLC
Shots: The companies plan to conduct a P-I/IIa trial assessing the safety and anti-tumor activity of SNK01 + gemcitabine/carboplatin or gemcitabine/carboplatin + Erbitux (cetuximab) in […]